Product Name: CDK5 (12-18) pY15
Product Number: PE-04AJO95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: CDK5 (12-18) pY15

Product Use: Services as a blocking peptide for use with the CDK5-pY15 rabbit polyclonal antibody (Cat. No.: AB-PK570) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain in subdomain I, which is involved in binding the phosphates in the ATP substrate. Phosphorylation inhibits phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EGT-pY-GTV

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 979.91 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: CDK5 - pY15 phosphosite-specific antibody (Cat. No.: AB-PK570)

Scientific Background: CDK5 is a protein-serine/threonine kinase of the CMGC group and CDK family. It is required for cell cycle arrest in neuronal cells. It is activated by binding p35 protein. Phosphorylation at S159 increases phosphotransferase activity. Phosphorylation at T14 and Y15 inhibits phosphotransferase activity. CDK5 has been observed to be proline-directed and to phosphorylate SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. CDK5 has been implicated in Aneurysmal bone cyst, which is a bone cancer that will affect bone, endothelial tissue, and bone marrow.